Skip to main content

Altimmune, Inc 10-Q for FY2026 Q3

Altimmune, Inc. (ALT)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

Altimmune, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Altimmune began enrolling patients in the global PERFORMA Phase 3 trial evaluating pemvidutide in MASH; the 52-week data readout to support accelerated approval is anticipated in 2029. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$31.61M
compared with a net loss of $19.01M a year earlier
Diluted EPS
-$0.15
compared with -$0.21 a year earlier